-
CAS NUMBER
320-67-2 -
FORMULATION
F - PARENTERAL ORDINARY (Injectables) -
THERAPEUTIC CATEGORY
L-ANTINEOPLASTIC & IMMUNOMODUL -
STATUS
Pipeline -
REGULATION
US DMF , EU DMF
-
About the API
-
Systematic Name: 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one
Trade Name(s): Vidaza
Molecular Formula: C8H12N4O5
Molecular Weight: 244.20 g/mol
Physical Properties: White to off- white powder
Therapeutic Category: Antimetabolites, antineoplastic – Enzyme inhibitors
-
-
API Expertise
-
The API expertise for producing Azacitidine is High Potent.
For more information about TAPI's expertise please click here
-
-
General
-
Azacitidine is used to treat myelodysplastic syndromes (MDS), a number of disorders in which not enough healthy blood cells are produced in the bone marrow, leaving patients with low blood counts. In healthy bone marrow, stem cells become red blood cells, white blood cells or platelets. In MDS, this process is dysfunctional. In a significant portion of patients, MDS progresses to a rapidly growing cancer of bone marrow cells called acute myeloid leukemia.
Administered through subcutaneous or intravenous injection, azacitidine is used for treatment of all five MDS subtypes (according to FAB classification): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions, refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Azacitidine belongs to the class of substances termed antimetabolites. Antimetabolites are drugs that interfere with the function of enzymes involved in DNA synthesis.
Azacitidine was approved by the FDA in 2004 under the trade name Vidaza as "the first effective treatment for patients with Myelodysplastic Syndrome (MDS)." It is designated as an orphan drug. Azacitidine is synthesized through a multi-step chemical process.
-
-
Mechanism of Action
-
Azacitidine works both directly, destroying abnormal cells in the bone marrow, and indirectly, by intervening in genetic processes.
Genes in the DNA are not always active, but are switched on and off. DNA methylation (the addition of methyl groups to cytosine in DNA) is one of several mechanisms that cells use to control gene expression. Too much methylation can lock genes – such as those responsible for tumor suppression or cell differentiation – in the "off" position.
Azacitidine reduces DNA methylation by posing as genetic material. It is incorporated into DNA, where it inhibits the enzyme that performs methylation (called DNA methyltransferase). This may "unlock" tumor suppressor genes as well as restore normal function to genes that are critical for differentiation.
Azacitidine is also incorporated into RNA, disrupting normal RNA function and inhibiting protein synthesis.
-
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact TAPI Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes
-
Visitors also viewed
-
9041-93-4
Bleomycin sulfate
Innovators / Marketer
Bristol Meyers SquibbFORMULATION
F - PARENTERAL ORDINARY (Injectables)THERAPEUTIC CATEGORY
L-ANTINEOPLASTIC & IMMUNOMODULAvailable DMF/CEP
- US DMF
- EU DMF
- Canada DMF
- Other
-
390800-88-1
Bortezomib
Innovators / Marketer
Millennium PharmaFORMULATION
F - PARENTERAL ORDINARY (Injectables)THERAPEUTIC CATEGORY
L-ANTINEOPLASTIC & IMMUNOMODULAvailable DMF/CEP
- US DMF
- EU DMF
- Japan DMF
- Korea DMF
- Canada DMF
- Brazil DMF
- Other
-
1402820-62-5
Cabazitaxel
Innovators / Marketer
Sanofi AventisFORMULATION
F - PARENTERAL ORDINARY (Injectables)THERAPEUTIC CATEGORY
L-ANTINEOPLASTIC & IMMUNOMODULAvailable DMF/CEP
- US DMF
- EU DMF
- Other
-
- Load More
-